Octagam
ApprovedSmall molecule
Octagam is one of 55 small molecule programs targeting Myocardial Infarction. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Octagam
OOslo University Hospital
Approved
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Tricor
JJagotec
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Nadroparin
GSKPreclinical
Calcium
Eli LillyPreclinical
Biological Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Exoflo
DDirect Biologics, LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Octagam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- OOslo University Hospital